Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIA Therapeutic dose of 600 mg varoglutamstat given twice daily selected by […]
Do you like it?
Data underscore the unique potential of Vivoryon’s N3pE-focused strategy in mono- and combination therapy settings in AD Combination treatment of aducanumab and varoglutamstat achieves additive effect […]
Do you like it?
Parallel group, dose-finding part of the study completed DSMB recommends that the study should proceed with a maximum dose of 600 mg BID varoglutamstat or placebo […]
Do you like it?
All proposed resolutions approved All existing members re-appointed Board strengthened and diversified HALLE (SAALE) / MUNICH, GERMANY, June 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: […]
Do you like it?
HALLE (SAALE) / MUNICH, GERMANY, June 15, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Do you like it?
Halle (Saale) / Munich, Germany, June 08, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Do you like it?
Halle (Saale) / Munich, Germany, May 11, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon; or the Company), a clinical stage company focused on discovery and development of […]
Do you like it?
Substantial progress in clinical development of QPCT/L inhibitor varoglutamstat, EU and U.S. clinical studies in AD on track FDA Fast Track designation for lead product candidate […]
Do you like it?
Halle (Saale) / Munich, Germany, April 21, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Do you like it?